Compugen Ltd. (CGEN)
$1.98-4.35%Close
SELLCRISIS · day 5
Key stats
Short interest · FINRA settlement 2026-09-30
- Market cap
- $187M
- Beta
- 2.79
- P/E (TTM)
- 5.33
- Short % float
- 2.55%
- Days to cover
- 16.1
- SI change
- -0.5%
- 1W
- -10.81%
- 1M
- -20.16%
- vs SPY 1W
- -10.67%
- vs SPY 1M
- -22.67%
Industry peers
FMP comparable companies · ranked by market cap
Prediction markets
Kalshi · Polymarket · … linked
Loading markets…
FUNDAMENTALS
[SCORES & PROFILE]
- FUND
- 35
- VALUE
- 35
- GROWTH
- 77
- GARP
- 15
- TYPE
- Balanced
Composite of Value · Growth · GARP
ROIC25.5%
REV YoY-
ROE42.6%
EPS YoY-
ROA25.4%
GROSS87
OP41
NET48
[VALUATION]
P/E TTM5.33
P/E FWD-
SECTOR PE20.48
INDUSTRY PE13.99
P/B2.13
P/FCF-
EV/EBITDA5.17
EV/EBIT-
PEG-
FCF YIELD-
RISK
INT COV-
D/E3.41
ALTMAN Z-
CURR RATIO5.72
ND/EBITDA-
BETA2.79
Company news
FAQ
- What is LOPJLB’s current signal on CGEN?
- LOPJLB’s latest quantitative signal on Compugen Ltd. (CGEN) is SELL in a CRISIS regime. Signals are updated daily.
- What market regime is CGEN in?
- Compugen Ltd. (CGEN) is currently classified in the CRISIS HMM market regime on LOPJLB.
- What does Compugen Ltd. (CGEN) do?
- Compugen Ltd., an Israeli-based company established in 1993 and headquartered in Holon, is a clinical-stage enterprise focused on the discovery, development, and commercialization of therapeutic and product candidates. Its operations extend across Israel, the United States, and Europe. The companyâs core activities center around its immuno-oncology pipeline, which includes several investigati…